Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.
Original Article: FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment